Search

Search


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Search results for {{term}}

161. NIHR Brain Injury Healthcare Technology Co-operative – Seedcorn Fundin

NIHR Brain Injury Healthcare Technology Co-operative – Seedcorn Funding Competition 2016/2017 – FUNDING CALL ROUND 2 NOW OPEN13/02/2017The NIHR Brain Injury Healthcare Technology Co-operative is pleased to announce the second round of its second national competition. The seed funding call (up to £10,000) is for the early development of novel technology-based solutions applicable to the brain injury pathway, from prevention of injury all the way through to technologies for indepe


162. Cell Lines & Media for Difficult to Culture Tumor Types

Cell Lines & Media for Difficult to Culture Tumor Types23/02/2017AMSBIO has introduced a new range of cancer cell line models and culture media for the most difficult to culture tumor types where no models may exist.Alex Sim, Managing Director at AMSBIO said, “Our new partnership with Cellaria Biosciences expands our existing portfolio by introducing patient-derived cancer models; allowing customers to conduct research and drug discovery initiatives to advance precision


163. Oxford Immunotec Reports Fourth Quarter and Full Year 2016 Financial R

Oxford Immunotec Reports Fourth Quarter and Full Year 2016 Financial Results27/02/2017Oxford, UK & Marlborough, USA – Oxford Immunotec Global PLC, a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced fourth quarter and full year 2016 financial results.“We are very pleased with our performance during the fourth quarter and throughout 2016, as we evolved f


164. »Lab282« Awarded First Projects. Oxford University and Evotec's Drug D

»Lab282« Awarded First Projects. Oxford University and Evotec's Drug Discovery Partnership Launched Last November to Accelerate Drugs to Market Begins Making Awards21/02/2017- Oxford University and Evotec's drug discovery partnership launched last November to accelerate drugs to market begins making awardsEvotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) is pleased to announce that LAB282, the £ 13 m (over EUR 15 m) drug discovery partnership with Oxford Univer


165. Apollo Therapeutics – Funding of Four Initial Projects and Operational

Apollo Therapeutics – Funding of Four Initial Projects and Operational Update22/02/2017> First four drug discovery programmes now launched in collaboration with academics at all three partner universities - spanning a variety of disease areas and drug modalities> Recruited highly experienced Project Directors with track records of delivering project success within big pharma> More than £8.5m committed to projects so far from a total budget of £40mApollo Therapeutics (



Page 33 of 44 ( 219 results in total )
© Catalyst Innovation Portal 2019